TrialHaematologica2014

A phase II study of vorinostat (MK-0683) in patients with primary myelofibrosis and post-polycythemia vera myelofibrosis.

Christen L Andersen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.